Imperial College London
Portrait Picture

DrGeorgiosNteliopoulos

Faculty of Medicine, Department of Surgery & Cancer

Research Associate Biomarker
 
 
 
//

Contact

 

georgios.nteliopoulos04

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Fernandez-Garcia:2022:10.1038/s41416-022-01962-9,
author = {Fernandez-Garcia, D and Nteliopoulos, G and Hastings, RK and Rushton, A and Page, K and Allsopp, RC and Ambasager, B and Gleason, K and Guttery, DS and Ali, S and Coombes, RC and Shaw, JA},
doi = {10.1038/s41416-022-01962-9},
journal = {British Journal of Cancer},
pages = {1858--1864},
title = {Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer},
url = {http://dx.doi.org/10.1038/s41416-022-01962-9},
volume = {127},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundWe report copy-number profiling by low-pass WGS (LP-WGS) in individual circulating tumour cells (CTCs) for guiding treatment in patients with metastatic breast cancer (MBC), comparing CTC results with mutations detected in circulating tumour DNA (ctDNA) in the same blood samples.MethodsAcross 10 patients with MBC who were progressing at the time of blood sampling and that had >20 CTCs detected by CellSearch®, 63 single cells (50 CTCs and 13 WBCs) and 16 cell pools (8 CTC pools and 8 WBC pools) were recovered from peripheral blood by CellSearch®/DEPArray™ and sequenced with Ampli1 LowPass technology (Menarini Silicon Biosystems). Copy-number aberrations were identified using the MSBiosuite software platform, and results were compared with mutations detected in matched plasma cfDNA analysed by targeted next-generation sequencing using the Oncomine™ Breast cfDNA Assay (Thermo Fisher).ResultsLP-WGS data demonstrated copy-number gains/losses in individual CTCs in regions including FGFR1, JAK2 and CDK6 in five patients, ERBB2 amplification in two HER2-negative patients and BRCA loss in two patients. Seven of eight matched plasmas also had mutations in ctDNA in PIK3CA, TP53, ESR1 and KRAS genes with mutant allele frequencies (MAF) ranging from 0.05 to 33.11%. Combining results from paired CTCs and ctDNA, clinically actionable targets were identified in all ten patients.ConclusionThis combined analysis of CTCs and ctDNA may offer a new approach for monitoring of disease progression and to direct therapy in patients with advanced MBC, at a time when they are coming towards the end of other treatment options.
AU  - Fernandez-Garcia,D
AU  - Nteliopoulos,G
AU  - Hastings,RK
AU  - Rushton,A
AU  - Page,K
AU  - Allsopp,RC
AU  - Ambasager,B
AU  - Gleason,K
AU  - Guttery,DS
AU  - Ali,S
AU  - Coombes,RC
AU  - Shaw,JA
DO  - 10.1038/s41416-022-01962-9
EP  - 1864
PY  - 2022///
SN  - 0007-0920
SP  - 1858
TI  - Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer
T2  - British Journal of Cancer
UR  - http://dx.doi.org/10.1038/s41416-022-01962-9
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000852356000004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR  - https://www.nature.com/articles/s41416-022-01962-9
UR  - http://hdl.handle.net/10044/1/101969
VL  - 127
ER  -
Download